KPV

KPV Peptide: Comprehensive Research Guide

KPV is a tripeptide with the sequence Lysine-Proline-Valine (Lys-Pro-Val), renowned for its potent anti-inflammatory, antimicrobial, and tissue repair properties. Originally identified as a fragment of the naturally occurring hormone α-melanocyte-stimulating hormone (α-MSH), KPV has emerged as a promising research tool in immunology, dermatology, gastroenterology, and regenerative medicine. With a molecular weight of just 343.45 Da, KPV is one of the smallest biologically active peptides, yet it exhibits remarkable therapeutic potential across multiple organ systems.

First characterized in the early 2000s, KPV was discovered to be the minimal active fragment responsible for the anti-inflammatory effects of α-MSH. Unlike the full-length α-MSH peptide, which acts primarily through melanocortin receptors (MC1R-MC5R), KPV exerts its effects through both receptor-dependent and receptor-independent mechanisms, including direct intracellular anti-inflammatory action. This unique mechanism of action, combined with its small size, excellent stability, and low immunogenicity, has made KPV an increasingly popular research tool. Researchers worldwide utilize high-purity KPV to investigate inflammatory bowel disease, skin disorders, wound healing, oral inflammation, and potential therapeutic applications for a wide range of inflammatory conditions.

Molecular Structure and Biological Activity

KPV is a simple tripeptide consisting of three amino acids: lysine (Lys, K), proline (Pro, P), and valine (Val, V). Despite its small size, KPV exhibits potent biological activity that belies its simple structure. Key molecular properties:

• AMINO ACID SEQUENCE: Lys-Pro-Val (K-P-V)
• MOLECULAR FORMULA: C₁₆H₂₉N₃O₄
• MOLECULAR WEIGHT: 343.45 Da
• STRUCTURE: Linear tripeptide, no disulfide bonds or post-translational modifications
• SOLUBILITY: Freely soluble in water, PBS, and physiological saline; highly soluble due to the charged lysine residue
• pI: Approximately 9.5 (basic peptide due to the N-terminal lysine amino group and lysine side chain)
• STABILITY: Highly stable in lyophilized form and aqueous solutions; resistant to many proteases due to the proline residue, which creates steric hindrance
• BIOAVAILABILITY: Excellent oral and topical bioavailability due to small molecular size and resistance to gastrointestinal degradation
• IMMUNOGENICITY: Very low immunogenicity due to small size and natural amino acid composition

Mechanism of Action

KPV exerts its biological effects through multiple complementary mechanisms, distinguishing it from many other anti-inflammatory peptides:

• INTRACELLULAR ANTI-INFLAMMATORY ACTION: The most distinctive feature of KPV is its ability to directly enter cells and exert anti-inflammatory effects from within, independent of cell surface receptors. KPV accumulates in the cytoplasm and nucleus, where it directly inhibits the activation and nuclear translocation of the pro-inflammatory transcription factor NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells). By blocking NF-κB signaling, KPV reduces the expression of a wide range of pro-inflammatory cytokines, chemokines, and adhesion molecules, including TNF-α, IL-1β, IL-6, IL-8, MCP-1, and ICAM-1.
• MELANOCORTIN RECEPTOR MODULATION: While KPV is less potent than full-length α-MSH at melanocortin receptors, it can still interact with MC1R and other melanocortin receptors at higher concentrations, contributing to its anti-inflammatory and immunomodulatory effects, particularly in skin and melanocyte-rich tissues.
• ANTIMICROBIAL ACTIVITY: KPV exhibits direct antimicrobial activity against a broad spectrum of bacteria, fungi, and viruses, including Staphylococcus aureus, Escherichia coli, Candida albicans, and herpes simplex virus. Its cationic nature (due to the lysine residue) allows it to interact with negatively charged microbial membranes, disrupting membrane integrity and inhibiting microbial growth. This antimicrobial activity makes KPV particularly useful for research on wound healing and infectious-inflammatory conditions.
• ANTIOXIDANT EFFECTS: KPV reduces oxidative stress by scavenging reactive oxygen species (ROS), upregulating antioxidant enzymes (such as superoxide dismutase and catalase), and inhibiting NADPH oxidase activity. By reducing oxidative stress, KPV protects cells from oxidative damage and reduces inflammation triggered by ROS-mediated signaling pathways.
• WOUND HEALING AND TISSUE REPAIR: KPV promotes wound healing and tissue repair through multiple mechanisms, including reducing inflammation, inhibiting microbial growth, promoting fibroblast proliferation and migration, stimulating collagen synthesis, enhancing angiogenesis, and accelerating re-epithelialization. Its ability to simultaneously address multiple aspects of the wound healing process (inflammation, infection, tissue formation, and remodeling) makes it particularly effective in research on impaired wound healing.
• IMMUNOMODULATION: KPV modulates both innate and adaptive immune responses, shifting the immune balance from a pro-inflammatory Th1/Th17 profile toward an anti-inflammatory Th2/Treg profile. It inhibits the activation and proliferation of pro-inflammatory immune cells (such as M1 macrophages, Th1 cells, and Th17 cells) while promoting the activity of anti-inflammatory and regulatory immune cells (such as M2 macrophages and regulatory T cells). This immunomodulatory effect is relevant to research on autoimmune diseases, chronic inflammatory conditions, and transplant tolerance.

Research Applications

1. Inflammatory Bowel Disease (IBD) Research

KPV is extensively studied in inflammatory bowel disease research, including Crohn’s disease and ulcerative colitis:

• Intestinal Inflammation: Research into KPV’s effects on intestinal inflammation, including its ability to reduce colonic inflammation, decrease inflammatory cytokine production, protect intestinal epithelial barrier function, and reduce histological damage in animal models of colitis. KPV’s direct intracellular anti-inflammatory action is particularly relevant in the intestine, where it can act directly on intestinal epithelial cells and immune cells in the lamina propria.
• Intestinal Barrier Function: Studies investigating KPV’s effects on intestinal epithelial barrier integrity, including its ability to maintain tight junction protein expression (such as occludin, claudin-1, and ZO-1), reduce intestinal permeability (“leaky gut”), and prevent bacterial translocation. Maintaining intestinal barrier function is critical in IBD, as barrier disruption allows luminal bacteria and antigens to enter the intestinal wall, triggering and perpetuating inflammation.
• Gut Microbiome: Research into KPV’s effects on the gut microbiome, including its antimicrobial activity against pathogenic bacteria while potentially preserving beneficial commensal bacteria, and its indirect effects on microbial composition through reduced intestinal inflammation and improved gut health. The gut microbiome plays a crucial role in IBD pathogenesis, and KPV’s ability to modulate both inflammation and microbial composition makes it a valuable research tool.
• Oral Bioavailability: Studies investigating KPV’s excellent oral bioavailability and gastrointestinal stability, which make it suitable for oral administration in IBD research. Unlike many larger peptides that are degraded in the gastrointestinal tract, KPV’s small size and proline-containing structure confer resistance to gastrointestinal proteases, allowing it to reach the colon in biologically active concentrations after oral administration.
• Combination Therapy Research: Research into KPV as an adjunct to conventional IBD therapies (such as aminosalicylates, corticosteroids, immunomodulators, and biologic agents), investigating potential synergistic effects, steroid-sparing properties, and improved therapeutic outcomes. KPV’s different mechanism of action (direct intracellular NF-κB inhibition) may complement conventional IBD therapies and reduce the need for high-dose corticosteroids or immunosuppressants.

2. Dermatology and Skin Research

KPV is widely studied in dermatology for its anti-inflammatory, antimicrobial, and wound healing properties:

• Inflammatory Skin Diseases: Research into KPV’s effects on inflammatory skin conditions, including psoriasis, atopic dermatitis (eczema), contact dermatitis, rosacea, and acne. KPV reduces skin inflammation by inhibiting NF-κB signaling, reducing inflammatory cytokine production, and modulating immune cell activity in the skin. Its antimicrobial activity is particularly relevant for acne and infected skin conditions, where it can reduce Cutibacterium acnes and other pathogenic bacteria while simultaneously reducing inflammation.
• Wound Healing: Studies investigating KPV’s effects on cutaneous wound healing, including its ability to accelerate wound closure, promote re-epithelialization, enhance collagen deposition, stimulate angiogenesis, reduce scar formation, and improve wound tensile strength. KPV’s ability to simultaneously reduce inflammation, inhibit infection, and promote tissue repair makes it particularly effective for research on impaired wound healing, including diabetic wounds, venous ulcers, pressure ulcers, and surgical wounds.
• Skin Aging and Photoaging: Research into KPV’s potential anti-aging effects on the skin, including its ability to reduce oxidative stress, inhibit matrix metalloproteinases (MMPs) that degrade collagen and elastin, promote collagen synthesis, improve skin elasticity, reduce wrinkle formation, and protect against UV-induced photoaging. KPV’s antioxidant and anti-inflammatory properties may help mitigate the effects of intrinsic and extrinsic skin aging.
• Skin Barrier Function: Studies investigating KPV’s effects on skin barrier function, including its ability to maintain epidermal differentiation, support ceramide and lipid production, reduce transepidermal water loss (TEWL), and improve skin hydration. A healthy skin barrier is essential for preventing water loss, protecting against environmental irritants and pathogens, and maintaining skin homeostasis. KPV may help restore barrier function in conditions like atopic dermatitis and sensitive skin.
• Topical Formulation Research: Research into KPV’s excellent skin penetration and suitability for topical formulations, including creams, ointments, gels, serums, and transdermal patches. KPV’s small molecular size (343 Da) allows it to penetrate the stratum corneum and reach the viable epidermis and dermis, where it can exert its biological effects. This makes KPV an attractive candidate for topical dermatological research and cosmetic science.

3. Oral and Dental Research

KPV is studied in oral and dental research for its anti-inflammatory, antimicrobial, and tissue repair properties:

• Periodontal Disease: Research into KPV’s effects on periodontal disease (gingivitis and periodontitis), including its ability to reduce gingival inflammation, inhibit periodontal pathogens (such as Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans), reduce alveolar bone loss, promote periodontal tissue regeneration, and improve clinical parameters such as probing depth, bleeding on probing, and clinical attachment level. KPV’s combination of anti-inflammatory and antimicrobial activities makes it particularly relevant for periodontal disease research.
• Oral Mucositis: Studies investigating KPV’s potential for the prevention and treatment of oral mucositis, a common and painful side effect of chemotherapy and radiation therapy. KPV may reduce oral mucosal inflammation, protect epithelial cells from chemotherapy/radiation-induced damage, accelerate mucosal healing, reduce pain, and improve oral intake in patients undergoing cancer treatment. Its antimicrobial activity may also help prevent secondary infections in ulcerated oral mucosa.
• Oral Wound Healing: Research into KPV’s effects on oral wound healing, including extraction sockets, surgical wounds, traumatic ulcers, and aphthous ulcers (canker sores). KPV accelerates oral wound healing through its anti-inflammatory, antimicrobial, and tissue-repairing properties, and its ability to function effectively in the oral environment (with its high moisture, enzymatic activity, and microbial load) makes it a valuable research tool for oral surgery and dental medicine.
• Dental Implant Research: Studies investigating KPV’s potential to improve dental implant outcomes, including reducing peri-implant inflammation, inhibiting bacterial colonization on implant surfaces, promoting osseointegration (bone integration with the implant), and preventing peri-implantitis. KPV may be applied as a coating on implant surfaces or administered locally to improve implant success rates, particularly in patients with compromised bone healing or increased infection risk.

4. Wound Healing and Regenerative Medicine Research

KPV is extensively studied in wound healing and regenerative medicine for its multifaceted effects on tissue repair:

• Chronic Wound Healing: Research into KPV’s effects on chronic, non-healing wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers (bedsores), and arterial insufficiency ulcers. Chronic wounds are characterized by persistent inflammation, impaired angiogenesis, reduced fibroblast activity, increased matrix metalloproteinase activity, and high bacterial burden. KPV addresses multiple aspects of chronic wound pathophysiology simultaneously: it reduces inflammation, inhibits microbial growth, promotes fibroblast proliferation and collagen synthesis, enhances angiogenesis, and accelerates re-epithelialization, making it a promising research tool for chronic wound treatment.
• Surgical Wound Healing: Studies investigating KPV’s effects on surgical wound healing, including its ability to reduce postoperative inflammation and infection, promote primary intention healing, improve wound tensile strength, reduce scar formation, and shorten recovery time. KPV may be applied topically to surgical incisions or administered systemically to improve surgical outcomes, particularly in patients at increased risk of wound complications (such as diabetics, obese patients, elderly patients, and immunocompromised individuals).
• Burn Wound Healing: Research into KPV’s effects on burn wound healing, including its ability to reduce burn-induced inflammation and oxidative stress, protect against burn progression (conversion of partial-thickness to full-thickness burns), inhibit burn wound infection, promote re-epithelialization, reduce scar contracture, and improve functional and cosmetic outcomes. Burn wounds are particularly susceptible to infection and excessive inflammation, and KPV’s combination of antimicrobial and anti-inflammatory activities may be especially beneficial.
• Scar Reduction and Tissue Remodeling: Studies investigating KPV’s effects on scar formation and tissue remodeling, including its ability to reduce hypertrophic scars and keloids, promote more organized collagen deposition, improve collagen fiber alignment, reduce myofibroblast persistence, and enhance extracellular matrix remodeling. By modulating the inflammatory phase of wound healing and promoting balanced tissue formation, KPV may help reduce excessive scarring and improve the quality of healed tissue.
• Organ and Tissue Repair: Emerging research into KPV’s potential for repairing damage to internal organs and tissues, including the liver (hepatitis, fibrosis), lungs (acute respiratory distress syndrome, pulmonary fibrosis), kidneys (nephritis, fibrosis), heart (myocarditis, myocardial infarction), and nervous system (neuroinflammation, neurodegeneration). KPV’s broad anti-inflammatory, antioxidant, and tissue-repairing properties, combined with its excellent bioavailability and low toxicity, make it a promising candidate for research on a wide range of inflammatory and degenerative conditions affecting multiple organ systems.

5. Immunology and Autoimmune Disease Research

KPV is studied in immunology and autoimmune disease research for its immunomodulatory properties:

• Autoimmune Disease Models: Research into KPV’s effects in animal models of autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, type 1 diabetes, autoimmune thyroiditis, and Sjögren’s syndrome. By inhibiting NF-κB signaling, reducing pro-inflammatory cytokine production, and shifting the immune balance toward anti-inflammatory and regulatory phenotypes, KPV may help reduce autoimmune inflammation and tissue damage. Its low toxicity and excellent bioavailability make it suitable for long-term administration in chronic autoimmune disease research.
• Sepsis and Systemic Inflammation: Studies investigating KPV’s effects in sepsis and systemic inflammatory response syndrome (SIRS), including its ability to reduce systemic inflammation, inhibit cytokine storm, protect organ function, improve hemodynamic stability, and reduce mortality in animal models of sepsis and endotoxemia. Sepsis is characterized by dysregulated systemic inflammation and immune dysfunction, and KPV’s ability to modulate both inflammatory and immune responses may help restore immune homeostasis and prevent organ damage.
• Allergic Inflammation: Research into KPV’s effects on allergic inflammation, including allergic rhinitis, allergic asthma, atopic dermatitis, and food allergies. KPV may reduce allergic inflammation by inhibiting mast cell degranulation, reducing histamine and inflammatory mediator release, modulating Th2 immune responses, and reducing eosinophil activation and recruitment. Its anti-inflammatory and immunomodulatory properties make it a valuable research tool for allergic disease mechanisms and potential treatments.
• Transplant Immunology: Studies investigating KPV’s potential in transplant immunology, including its ability to reduce allograft rejection, promote transplant tolerance, reduce ischemia-reperfusion injury, and allow reduction of immunosuppressive drug doses. By modulating immune responses and promoting regulatory T cell activity, KPV may help prevent transplant rejection while preserving protective immunity against infections. Its low toxicity and lack of generalized immunosuppression make it an attractive candidate for transplant research.

6. Ophthalmology and Eye Research

KPV is increasingly studied in ophthalmology for its anti-inflammatory and tissue-repairing properties:

• Ocular Surface Inflammation: Research into KPV’s effects on ocular surface inflammatory conditions, including dry eye disease, blepharitis, conjunctivitis, and contact lens-induced inflammation. KPV may reduce ocular surface inflammation, improve tear film stability, reduce corneal and conjunctival staining, alleviate symptoms of dryness and irritation, and promote ocular surface healing. Its antimicrobial activity may also help prevent and treat ocular surface infections. KPV’s excellent tolerance and low toxicity make it suitable for ophthalmic formulations such as eye drops and ointments.
• Corneal Wound Healing: Studies investigating KPV’s effects on corneal wound healing, including corneal abrasions, surgical wounds (such as after LASIK or cataract surgery), corneal ulcers, and chemical burns. KPV accelerates corneal epithelial wound healing, reduces corneal inflammation and neovascularization, inhibits corneal infection, and preserves corneal transparency. Its ability to promote rapid re-epithelialization while reducing inflammation and scarring makes it valuable for corneal research and potentially for clinical ophthalmology.
• Uveitis and Intraocular Inflammation: Research into KPV’s effects on uveitis and other intraocular inflammatory conditions, including anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis. KPV may reduce intraocular inflammation, inhibit inflammatory cell infiltration into the eye, reduce retinal and choroidal inflammation, preserve visual function, and reduce the need for corticosteroid and immunosuppressive therapy. Its ability to cross ocular barriers and exert direct intracellular anti-inflammatory effects makes it a promising research tool for ocular inflammatory diseases.
• Retinal Diseases: Emerging research into KPV’s potential for retinal diseases with inflammatory components, including age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, and retinitis pigmentosa. KPV may reduce retinal inflammation and oxidative stress, protect retinal pigment epithelial cells and photoreceptors, inhibit choroidal neovascularization, and preserve visual function. Its neuroprotective and anti-angiogenic properties, combined with its anti-inflammatory effects, make it a candidate for research on retinal degenerative diseases.

Product Specifications

Parameter	Value
Compound Name	KPV (Lys-Pro-Val Tripeptide)
Amino Acid Sequence	Lys-Pro-Val (K-P-V)
CAS Number	67727-97-3
Molecular Formula	C₁₆H₂₉N₃O₄
Molecular Weight	343.45 Da
Purity	≥98% (HPLC verified)
Appearance	White to off-white lyophilized powder
Solubility	Freely soluble in water, PBS, 0.9% NaCl
Specific Rotation	[α]₂₀ᴰ = -70° to -80° (c=1, water)
Water Content	≤5% (Karl Fischer)
Endotoxin	<1 EU/mg (LAL method)
Storage	-20°C, sealed, protected from light and moisture
Shelf Life	24 months from date of manufacture

Reconstitution and Handling Guidelines

For optimal results in laboratory research:

1. Allow the vial to equilibrate to room temperature before opening to prevent condensation
2. Reconstitute with sterile water, 0.9% NaCl, PBS, or bacteriostatic water to a desired concentration (typically 1-50 mg/mL; KPV is highly soluble)
3. Gently swirl the vial until complete dissolution; KPV dissolves readily and does not require vigorous mixing
4. For cell culture experiments, filter-sterilize the reconstituted solution using a 0.22 μm filter
5. Aliquot into working volumes to avoid repeated freeze-thaw cycles
6. Store lyophilized powder at -20°C; store reconstituted solutions at -20°C or -80°C for long-term use
7. Reconstituted solutions are stable for 14-30 days at 2-8°C (KPV is highly stable in solution) and up to 6 months at -20°C
8. Avoid exposure to extreme pH (KPV is most stable at pH 4-8) and high temperatures
9. KPV is suitable for oral, topical, intravenous, subcutaneous, intraperitoneal, and local administration routes in research

Frequently Asked Questions (FAQ)

Q1: What is the difference between KPV and α-MSH?

KPV (Lys-Pro-Val) is a tripeptide fragment derived from the C-terminal region of α-melanocyte-stimulating hormone (α-MSH), a 13-amino acid peptide involved in melanin production, inflammation regulation, and energy homeostasis. While KPV was originally identified as the minimal active fragment responsible for α-MSH’s anti-inflammatory effects, the two peptides differ significantly in their mechanisms and biological activities:
– Mechanism: α-MSH acts primarily through cell surface melanocortin receptors (MC1R-MC5R), activating cAMP signaling pathways. KPV, in contrast, can directly enter cells and exert intracellular anti-inflammatory effects by inhibiting NF-κB activation, independent of melanocortin receptors (although it can also interact with MC1R at higher concentrations).
– Melanogenic activity: α-MSH strongly stimulates melanin production (melanogenesis) through MC1R activation on melanocytes, which can cause skin darkening. KPV has minimal melanogenic activity, making it more suitable for research and potential therapeutic applications where skin darkening is undesirable.
– Size and stability: KPV is much smaller (3 amino acids, 343 Da) than α-MSH (13 amino acids, 1665 Da), giving KPV better bioavailability, improved tissue penetration, higher stability, and lower immunogenicity.
– Receptor selectivity: α-MSH activates all melanocortin receptors with varying affinity, producing a wide range of effects including melanogenesis, anti-inflammatory action, appetite regulation, and sexual function effects. KPV is more selective for anti-inflammatory effects, with fewer off-target activities.
In summary, KPV retains the potent anti-inflammatory properties of α-MSH while offering improved stability, better bioavailability, lower immunogenicity, and reduced melanogenic and other off-target effects, making it a more practical and versatile research tool for inflammatory conditions.

Q2: What purity level is recommended for research?

For most research applications, ≥98% purity (HPLC verified) is recommended. Our KPV meets this standard and undergoes comprehensive quality control, including mass spectrometry verification (confirming molecular weight of 343.45 Da), amino acid analysis, chiral purity verification (confirming L-amino acid configuration), endotoxin testing (<1 EU/mg), and microbial screening. For highly sensitive in vivo studies, cell culture experiments, ophthalmic research, or clinical research, we can provide ≥99% purity with additional quality testing (including peptide mapping, residual solvent testing, heavy metal analysis, and bioburden testing) upon request. KPV is a simple tripeptide with no post-translational modifications, making it relatively easy to synthesize at high purity, and our manufacturing process ensures consistent quality across batches. Note that KPV's high purity and simple composition contribute to its excellent safety profile and low incidence of adverse effects in research studies.

Q3: Can KPV be used in cell culture experiments?

Yes, KPV is highly suitable for cell culture experiments with a wide range of cell types, including intestinal epithelial cells (Caco-2, HT-29, T84), keratinocytes and fibroblasts (HaCaT, NHDF, 3T3), immune cells (macrophages, monocytes, T cells, B cells, dendritic cells), oral epithelial cells, corneal epithelial cells, hepatocytes, renal cells, pulmonary cells, and neuronal cells. It is highly soluble in standard culture media and exhibits excellent stability, with minimal degradation over extended culture periods. Typical working concentrations range from 1 μg/mL to 100 μg/mL (approximately 3 μM to 300 μM), depending on the cell type and assay. The EC50 for anti-inflammatory activity is typically in the range of 1-10 μg/mL. KPV is well-tolerated by cells at concentrations up to 1 mg/mL, with minimal cytotoxicity observed in most cell types. For extended experiments (>7 days), KPV remains stable in culture media, although periodic media refreshment is recommended as standard practice. Filter-sterilize reconstituted solutions before adding to cell cultures. KPV’s direct intracellular mechanism of action means that it can be studied in cells with or without melanocortin receptor expression, making it a versatile tool for investigating NF-κB signaling and inflammatory pathways in diverse cell types.

Q4: What is the typical dosage range for animal studies?

Dosage varies by species, administration route, and research objective. KPV has a wide therapeutic window and is well-tolerated at high doses. Common ranges include:
– Rodents (acute): 0.1-50 mg/kg (IP/SC/IV/oral), typically administered 1-3 times daily
– Rodents (chronic): 0.1-20 mg/kg/day (oral gavage, drinking water, SC injection, or osmotic minipump), typically for 2-12 weeks
– Rabbits/guinea pigs: 0.1-10 mg/kg (oral/topical/SC)
– Primates: 0.01-5 mg/kg (oral/SC/IV)
– Topical application: 0.1-5% KPV in cream, ointment, or gel formulation, applied 1-3 times daily
– Ophthalmic: 0.1-2% KPV in eye drop formulation, administered 2-4 times daily
KPV’s excellent oral bioavailability (estimated 50-80% in rodents due to small size and protease resistance) makes oral administration a convenient and effective route for many studies. For local tissue targeting (such as skin wounds, oral lesions, or ocular conditions), topical or local administration is often preferred to achieve high local concentrations while minimizing systemic exposure. Researchers should consult relevant literature and perform dose-response studies to optimize protocols for their specific applications. Note that KPV has shown minimal toxicity even at very high doses (up to 500 mg/kg in acute rodent studies), indicating a wide safety margin.

Q5: How does KPV compare to other anti-inflammatory peptides?

KPV differs from other anti-inflammatory peptides in several key aspects:
– vs. BPC-157: BPC-157 is a 15-amino acid peptide with potent healing and cytoprotective effects, but its mechanism of action is less well-defined and it may act through multiple pathways including growth factor receptor modulation. KPV is a smaller tripeptide with a well-characterized mechanism (direct NF-κB inhibition) and more focused anti-inflammatory and antimicrobial activity. Both peptides promote wound healing, but KPV has stronger antimicrobial activity while BPC-157 may have stronger angiogenic and tendon/ligament healing effects.
– vs. TB-500 (Thymosin Beta-4): TB-500 is a 43-amino acid peptide (or active fragment) involved in actin regulation, cell migration, and tissue repair. It has anti-inflammatory effects but is primarily known for its role in cell migration and angiogenesis. KPV is smaller, more stable, and has more direct anti-inflammatory and antimicrobial effects, while TB-500 may have stronger effects on cell migration and tissue remodeling.
– vs. GHK-Cu: GHK-Cu is a tripeptide (Gly-His-Lys) complexed with copper, known for its wound healing, anti-aging, and tissue remodeling effects. It acts through multiple mechanisms including gene expression modulation and copper delivery. KPV (Lys-Pro-Val) is a different tripeptide with stronger anti-inflammatory and antimicrobial activity, while GHK-Cu may have stronger effects on collagen synthesis, skin rejuvenation, and hair growth. Both are small, stable tripeptides with excellent safety profiles.
– vs. Thymosin Alpha-1: Thymosin alpha-1 is a 28-amino acid peptide with immunomodulatory effects, primarily used for immune enhancement and as an adjuvant in cancer and infectious disease treatment. It acts through Toll-like receptor and immune signaling pathways. KPV has more direct anti-inflammatory effects and broader tissue repair activity, while thymosin alpha-1 is more focused on immune enhancement and antiviral/anticancer immunity.
– vs. LL-37: LL-37 is a 37-amino acid antimicrobial peptide (cathelicidin) with broad-spectrum antimicrobial activity and immunomodulatory effects. It is larger, more expensive, and can be cytotoxic at higher concentrations. KPV is smaller, more stable, less expensive, and has minimal cytotoxicity, while still retaining significant antimicrobial activity combined with potent anti-inflammatory effects.
In summary, KPV offers a unique combination of small size, excellent stability, high bioavailability, low toxicity, potent anti-inflammatory activity, broad-spectrum antimicrobial effects, and tissue repair properties, making it a versatile and valuable research tool for a wide range of inflammatory, infectious, and wound healing conditions.

Q6: Is KPV stable in solution?

KPV is exceptionally stable in solution compared to most peptides, due to its small size, simple structure, and the presence of proline (which creates steric hindrance and confers resistance to many proteases). In neutral aqueous solutions (pH 6-8) at refrigerated temperatures (2-8°C), reconstituted KPV is stable for at least 14-30 days, with minimal degradation observed. For long-term storage, reconstituted solutions should be aliquoted and stored at -20°C or -80°C, where they remain stable for up to 6 months or longer. KPV is also relatively stable at room temperature for short periods (days to weeks), although refrigeration is recommended for long-term storage. It is resistant to degradation by many common proteases and peptidases, including gastrointestinal enzymes, which contributes to its excellent oral bioavailability. Avoid exposure to extreme pH (below pH 3 or above pH 10 for extended periods), high temperatures (>60°C), and strong oxidizing agents, as these conditions may cause degradation. For in vivo experiments, KPV solutions can be prepared in advance and stored refrigerated for multi-day studies, particularly when using bacteriostatic water or saline. For cell culture experiments, KPV remains stable in culture media for the duration of most standard experiments (3-7 days), although periodic media refreshment is recommended as standard practice. The high stability of KPV simplifies handling and storage compared to many larger, more labile peptides, and contributes to its reproducibility in research studies.

Q7: Can KPV be used in combination with other peptides or treatments?

Yes, KPV is frequently used in combination with other agents in research settings, and some of the most common combinations include:
– Combination with BPC-157: This is a popular combination for wound healing and tissue repair research, as KPV and BPC-157 have complementary mechanisms of action. KPV provides strong anti-inflammatory and antimicrobial effects, while BPC-157 promotes angiogenesis, cell migration, and tissue regeneration. The combination may be particularly effective for chronic wounds, musculoskeletal injuries, and gastrointestinal healing.
– Combination with GHK-Cu: Used in dermatology and skin aging research, combining KPV’s anti-inflammatory and antimicrobial effects with GHK-Cu’s collagen-stimulating and skin rejuvenating properties. This combination may be beneficial for acne, rosacea, wound healing, and anti-aging skincare research.
– Combination with TB-500 (Thymosin Beta-4): Used for tissue repair and regeneration research, combining KPV’s anti-inflammatory and antimicrobial effects with TB-500’s cell migration and tissue remodeling effects. This combination may be useful for wound healing, muscle injuries, and connective tissue repair.
– Combination with growth factors (EGF, FGF, PDGF, VEGF): Used in wound healing and regenerative medicine research, combining KPV’s anti-inflammatory and antimicrobial effects with growth factors’ direct stimulation of cell proliferation, migration, and tissue formation. KPV may create a more favorable inflammatory environment for growth factor-mediated tissue repair.
– Combination with antibiotics or antifungals: Used in infectious disease and wound infection research, combining KPV’s intrinsic antimicrobial activity with conventional antimicrobial agents. KPV may enhance the efficacy of antibiotics, reduce required doses, and help prevent antibiotic resistance, particularly in biofilm-associated infections.
– Combination with corticosteroids or immunosuppressants: Used in autoimmune disease and severe inflammation research, combining KPV’s anti-inflammatory effects with conventional immunosuppressive therapy. KPV may have steroid-sparing effects, allowing reduction of corticosteroid doses and associated side effects while maintaining therapeutic efficacy.
– Combination with probiotics or prebiotics: Used in inflammatory bowel disease and gut health research, combining KPV’s intestinal anti-inflammatory and barrier-protective effects with microbiome-modulating agents. This combination may address both the inflammatory and microbial aspects of IBD.
Researchers should carefully design combination studies, including appropriate controls for each agent alone and in combination, to assess synergistic, additive, or antagonistic effects. Note that KPV’s wide therapeutic window and low toxicity make it well-suited for combination studies, and no significant drug interactions have been reported in the literature to date.

Related Research Peptides

Researchers studying KPV often explore these complementary peptides:

• BPC-157 – 15-amino acid peptide with potent cytoprotective, healing, and regenerative effects; commonly combined with KPV for wound healing
• TB-500 (Thymosin Beta-4) – 43-amino acid peptide involved in actin regulation, cell migration, angiogenesis, and tissue repair
• GHK-Cu – Tripeptide (Gly-His-Lys) copper complex with wound healing, anti-aging, and tissue remodeling effects
• LL-37 – 37-amino acid antimicrobial peptide (cathelicidin) with broad-spectrum antimicrobial and immunomodulatory effects
• Thymosin Alpha-1 – 28-amino acid immunomodulatory peptide with immune-enhancing and antiviral effects
• Epitalon – Tetrapeptide (Ala-Glu-Asp-Gly) with telomere regulation and anti-aging effects
• Humanin – Mitochondrial-derived peptide with cytoprotective, neuroprotective, and metabolic effects
• MOTS-c – Mitochondrial-derived peptide with metabolic regulatory and exercise-mimetic effects

Quality Assurance

Our KPV is manufactured under strict GMP conditions and undergoes comprehensive quality testing:

• HPLC purity analysis (≥98%)
• Mass spectrometry molecular weight verification (confirming 343.45 Da)
• Amino acid composition analysis and sequencing
• Chiral purity verification (confirming L-Lys, L-Pro, L-Val configuration)
• Specific rotation measurement
• Peptide mapping and identity verification
• Water content determination (Karl Fischer, ≤5%)
• Endotoxin testing (LAL method, <1 EU/mg)
• Microbial contamination screening (bioburden testing)
• Biological activity verification (anti-inflammatory assay in LPS-stimulated macrophages; antimicrobial activity testing)
• Residual solvent testing (TFA, acetonitrile, methanol)
• Heavy metal analysis (for high-purity grades)

Each batch is accompanied by a Certificate of Analysis (COA) detailing all test results, including purity, molecular weight, chiral purity, and biological activity. We maintain complete batch records for full traceability and regulatory compliance. Custom synthesis of KPV analogs, labeled peptides (isotopic, fluorescent, biotinylated), modified formulations (including topical creams, ophthalmic solutions, and oral formulations), and combination products (e.g., KPV + BPC-157 blends) is available upon request. We also offer custom peptide synthesis services for researchers requiring modified KPV sequences or related peptides.

Important Disclaimer

FOR RESEARCH USE ONLY. This product is intended exclusively for laboratory and scientific research purposes. It is not approved for human consumption, clinical diagnosis, therapeutic treatment, veterinary use, or cosmetic formulation, except where specifically approved by regulatory authorities for indicated medical uses. KPV is a biologically active peptide with anti-inflammatory, antimicrobial, and immunomodulatory effects; all experiments must be conducted by qualified researchers in accordance with institutional biosafety guidelines, animal care protocols, and applicable regulations. Purchasers assume full responsibility for proper handling, storage, and use of this research material. This product is not intended for self-administration or use outside of approved research settings. Researchers should note that while KPV has demonstrated an excellent safety profile and low toxicity in preclinical studies, its long-term safety and efficacy in humans have not been fully established, and further research is needed before any clinical applications can be recommended. In vivo studies should be conducted with appropriate ethical review and monitoring of relevant physiological parameters, including inflammatory markers, immune function, microbial flora, and organ function. The use of KPV for performance enhancement, bodybuilding, or other non-research purposes is not endorsed, and researchers should be aware of the regulatory and ethical considerations surrounding the use of bioactive peptides in both research and potential clinical settings.